Provided by Tiger Trade Technology Pte. Ltd.

Aprea Therapeutics, Inc.

0.9330
-0.1070-10.29%
Volume:110.88K
Turnover:105.20K
Market Cap:5.89M
PE:-0.44
High:1.04
Open:1.04
Low:0.9000
Close:1.04
52wk High:5.00
52wk Low:0.9000
Shares:6.31M
Float Shares:4.32M
Volume Ratio:5.75
T/O Rate:2.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1364
EPS(LYR):-2.3519
ROE:-74.72%
ROA:-41.90%
PB:0.54
PE(LYR):-0.40

Loading ...

Aprea Therapeutics Inc - Net Proceeds Expected to Fund Aprea Into 2027

THOMSON REUTERS
·
2 hours ago

Press Release: Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dow Jones
·
2 hours ago

Aprea Therapeutics Reports Continued Clinical Progress and Extends Cash Runway Into Q4 2026

Reuters
·
Nov 12

Aprea Therapeutics Advances WEE1 Inhibitor APR-1051 in Phase 1 Trial for Hard-to-Treat Cancers

Reuters
·
Nov 12

Aprea Therapeutics Inc - Has Cash Runway Into Q4 2026

THOMSON REUTERS
·
Nov 12

Aprea Therapeutics Q3 Net Income USD -3 Million

THOMSON REUTERS
·
Nov 12

BRIEF-Aprea Sees Early Activity in APR-1051 Wee1 Trial

Reuters
·
Oct 24

Aprea Therapeutics Provides Clinical Update From Acesot-1051 Trial Showing Early Signals of Activity for Wee1 Kinase Inhibitor Apr-1051

THOMSON REUTERS
·
Oct 24

Aprea Therapeutics Inc - No Dose Limiting Toxicities or Unexpected Safety Issues Reported

THOMSON REUTERS
·
Oct 24

Aprea Therapeutics Inc - Dose Escalation Continues With 150 Mg Cohort Enrollment

THOMSON REUTERS
·
Oct 24

Aprea Therapeutics Announces Presentations at Eortc-Nci-Aacr International Conference on Molecular Targets and Cancer Therapeutics

THOMSON REUTERS
·
Oct 14

Aprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 12

Aprea Therapeutics Reports Q2 2025 Results: Net Loss Narrows to $3.2M, EPS Improves to $0.53 from $0.58

Reuters
·
Aug 12

Aprea Therapeutics Q2 EPS USD -0.53

THOMSON REUTERS
·
Aug 12

Aprea Therapeutics Inc expected to post a loss of 74 cents a share - Earnings Preview

Reuters
·
Aug 09

Aprea Says APR-1051 Shows Early Disease Control in HPV-Positive Head and Neck Cancer

MT Newswires Live
·
Jun 25

BRIEF-Aprea Reports Promising Early Data for WEE1 Inhibitor in HPV+ HNSCC with MD Anderson

Reuters
·
Jun 25